Sight Sciences, Inc. (SGHT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sight Sciences, Inc. (SGHT) Healthcare & Pipeline Overview

Sight Sciences, Inc. develops and commercializes surgical and nonsurgical ophthalmic technologies, including the OMNI Surgical System for glaucoma and TearCare System for dry eye. The company serves hospitals, medical centers, and eyecare professionals in the United States, addressing significant unmet needs in the treatment of eye diseases.

What Is the Investment Thesis for SGHT?

Sight Sciences presents a notable research candidate within the ophthalmic medical device sector. The company's innovative OMNI Surgical System and TearCare System address significant unmet needs in glaucoma and dry eye disease treatment, respectively. With a gross margin of 86.2%, Sight Sciences demonstrates strong pricing power and efficient operations. Growth catalysts include expanding market penetration of both OMNI and TearCare, coupled with potential for international expansion. However, investors should be aware of the company's negative profit margin of -46.8% and a beta of 2.49, indicating higher volatility compared to the market. Successful execution of commercialization strategies and continued innovation will be critical for long-term value creation.

Based on FMP financials and quantitative analysis

SGHT Key Highlights

Market capitalization of $443M reflects investor valuation of Sight Sciences' growth potential in the ophthalmic device market.

• Gross margin of 86.2% indicates strong pricing power and efficient manufacturing processes.
• Negative profit margin of -46.8% highlights the company's current focus on growth and investment in sales and marketing.
• Beta of 2.49 suggests higher volatility compared to the overall market, potentially due to its growth stage and market sensitivity.
• The company's focus on glaucoma and dry eye disease addresses large and growing markets with significant unmet needs.

Who Are SGHT's Competitors?

SGHT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SGHT's Key Strengths?

Innovative product portfolio addressing unmet needs in glaucoma and dry eye disease.

• High gross margin indicating strong pricing power.
• Established distribution network in the United States.
• Experienced management team with expertise in ophthalmic devices.

What Are SGHT's Weaknesses?

Negative profit margin reflecting ongoing investments in growth.

• High beta indicating greater volatility compared to the market.
• Reliance on a limited number of products.
• Limited international presence.

What Could Drive SGHT Stock Higher?

Publication of clinical data supporting the efficacy of OMNI Surgical System and TearCare System.

• Expansion of sales and marketing efforts to increase market penetration.
• Potential regulatory approvals for new applications of existing technologies.
• Continued innovation in ophthalmic device technology.
• Increasing awareness of glaucoma and dry eye disease.

What Are the Key Risks for SGHT?

Financial-distress signal — its Altman Z-Score of 0.69 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-50.6%) — the business is not currently generating profit on shareholder capital.
• Competition from established players in the ophthalmic device market.
• Regulatory hurdles and reimbursement pressures.
• Product liability claims.
• Economic downturn impacting healthcare spending.
• Dependence on key personnel.

What Are the Growth Opportunities for SGHT?

• Expansion of OMNI Surgical System market penetration: The OMNI Surgical System addresses the glaucoma market, which is projected to grow due to the aging global population. Increased adoption by ophthalmic surgeons, driven by clinical data and effective sales strategies, represents a significant growth opportunity for Sight Sciences. Focusing on key opinion leaders and expanding the sales force can accelerate market penetration.
• Increased adoption of TearCare System for dry eye disease: The TearCare System targets the dry eye disease market, a large and growing segment driven by factors such as increased screen time and environmental conditions. Expanding awareness among optometrists and ophthalmologists, along with demonstrating the clinical benefits of TearCare, can drive increased adoption and revenue growth. The company can also explore partnerships with eyecare clinics and chains.
• Development of new applications for existing technologies: Sight Sciences can leverage its existing technology platforms, such as the OMNI Surgical System and TearCare System, to develop new applications and address additional ophthalmic conditions. This could involve expanding the indications for these devices or creating new products based on the same underlying technology. Investing in research and development is crucial for identifying and pursuing these opportunities.
• Geographic expansion beyond the United States: Sight Sciences currently focuses on the U.S. market. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. This would require obtaining regulatory approvals in these regions and establishing distribution networks. Conducting market research to identify the most promising international markets is essential.
• Strategic acquisitions and partnerships: Sight Sciences can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, or enter new markets. This could involve acquiring companies with complementary products or partnering with research institutions to develop innovative solutions. A disciplined approach to M&A and partnership activities is crucial for maximizing value creation.

What Are SGHT's Competitive Advantages?

• Proprietary technology in the OMNI Surgical System and TearCare System.
• Established relationships with ophthalmic surgeons and eyecare professionals.
• Strong gross margin reflects pricing power and product differentiation.
• Focus on underserved markets within ophthalmology.

What Does SGHT Do?

Sight Sciences, Inc., founded in 2010 and headquartered in Menlo Park, California, is an ophthalmic medical device company dedicated to transforming the treatment of eye diseases. The company focuses on developing and commercializing innovative surgical and nonsurgical technologies. Its flagship products include the OMNI Surgical System and the TearCare System. The OMNI Surgical System is a therapeutic device utilized by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients, offering a minimally invasive approach to address this prevalent condition. The TearCare System is a wearable eyelid technology designed for the treatment of dry eye disease (DED), providing ophthalmologists and optometrists with a novel solution to alleviate symptoms and improve patient outcomes. Sight Sciences distributes its products through a network of sales representatives and distributors, reaching hospitals, medical centers, and eyecare professionals across the United States. The company is committed to advancing the field of ophthalmology through cutting-edge technology and a patient-centric approach.

What Products and Services Does SGHT Offer?

• Develops and commercializes surgical technologies for glaucoma treatment.
• Offers the OMNI Surgical System to reduce intraocular pressure in glaucoma patients.
• Creates nonsurgical technologies for dry eye disease (DED) treatment.
• Provides the TearCare System, a wearable eyelid technology for DED.
• Sells products to hospitals, medical centers, and eyecare professionals.
• Distributes products through sales representatives and distributors in the United States.

How Does SGHT Make Money?

• Sells OMNI Surgical System and TearCare System to ophthalmic surgeons and eyecare professionals.
• Generates revenue through direct sales and distributor partnerships.
• Focuses on providing innovative solutions for glaucoma and dry eye disease.
• Invests in research and development to expand product offerings.

What Industry Does SGHT Operate In?

The medical device industry, particularly the ophthalmic segment, is characterized by continuous innovation and increasing demand driven by an aging population and rising prevalence of eye diseases. Sight Sciences operates in a competitive landscape that includes established players and emerging companies. The company's focus on minimally invasive surgical and nonsurgical solutions positions it favorably within the market. The industry is also subject to regulatory scrutiny and reimbursement pressures, requiring companies to demonstrate clinical efficacy and cost-effectiveness.

Who Are SGHT's Key Customers?

• Ophthalmic surgeons who treat glaucoma patients.
• Optometrists who treat dry eye disease patients.
• Hospitals and medical centers that offer ophthalmic procedures.
• Eyecare professionals seeking advanced treatment options.

Wall Street analysts project Sight Sciences, Inc. revenue of about $89.1M for fiscal 2026, with EPS near $-0.63. The estimate reflects 5 contributing analysts.

Sight Sciences, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 15.8% above estimates on average.

Sight Sciences, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.69 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Sight Sciences, Inc. stands at -50.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.6%, the inverse of the P/E and a quick read on earnings relative to price.

Sight Sciences, Inc. (SGHT) Valuation Context

Valued at $443M, SGHT is classified as a small-cap stock. Relative to its peer group, SGHT's quantitative score of 27/100 is below the peer average of 69/100.

SGHT Revenue & Earnings Trend

In Q2 2026, SGHT generated $23.4M in top-line revenue, marking a sequential increase of 18.7%. The company recorded a net loss of $4.4M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, SGHT averaged $-0.14 in diluted EPS.

Company Profile

Sight Sciences, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Menlo Park, US. The company is led by CEO Paul Badawi. SGHT has traded publicly since 2021.

SGHT Financials

SGHT Latest News

SGHT Analyst Consensus

SGHT MoonshotScore

SGHT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources